Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | FSHR | P23945 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16755148 | 0.85 | GCK (0.50) | GCKNPC1RAB9APOLBCXCR2 | |
| SCHEMBL22607251 | 0.84 | RAB9A (0.59) | NPC1RAB9APOLBTSHRFSHR | |
| SCHEMBL5143604 | 0.83 | DEGS1 (0.65) | GCKNPC1RAB9APOLBTSHR | |
| SCHEMBL24616597 | 0.83 | SMN1; SMN2 (0.54) | GCKNPC1RAB9APOLBTSHR | |
| SCHEMBL30471306 | 0.82 | GCK (0.50) | GCKNPC1RAB9APOLBCXCR2 | |
| SCHEMBL16841480 | 0.82 | RAB9A (0.57) | GCKRAB9ACXCR2ALDH1A1MAPT | |
| SCHEMBL7090892 | 0.81 | POLB (0.52) | NPC1RAB9APOLBTSHRSMN1; SMN2 | |
| SCHEMBL18216846 | 0.81 | TRPV1 (0.52) | NPC1RAB9APOLBTSHRFSHR | |
| SCHEMBL22607138 | 0.81 | MEN1 (0.49) | GCKNPC1RAB9APOLBTSHR | |
| SCHEMBL31307412 | 0.80 | POLB (0.51) | GCKNPC1RAB9APOLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0842924-B1 | Pyridine intermediates, useful in the synthesis of beta-adrenergic receptor agonists | PFIZER (US) | 2003-08-20 | — | — | EP | claimed |
| EP-0842924-A1 | Pyridine intermediates, useful in the synthesis of beta-adrenergic receptor agonists | PFIZER INC. (US) | 1998-05-20 | — | — | EP | claimed |
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEONE MEDICINES I GMBH (CH) | 2025-11-13 | — | — | US | disclosed |
| US-20210147403-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-05-20 | — | — | US | disclosed |
| US-10882855-B2 | Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-01-05 | — | — | US | disclosed |
| US-20190263795-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-08-29 | — | — | US | disclosed |
| US-10336741-B2 | Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-07-02 | — | — | US | disclosed |
| EP-3056493-B1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISEASES | ONO PHARMACEUTICAL CO (JP) | 2017-07-12 | — | — | EP | disclosed |
| US-20170137412-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-05-18 | — | — | US | disclosed |
| US-9585881-B2 | Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-03-07 | — | — | US | disclosed |
| US-20160287582-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-10-06 | — | — | US | disclosed |
| US-9394250-B2 | Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-07-19 | — | — | US | disclosed |
| US-20150152048-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2855452-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | ONO Pharmaceutical Co., Ltd. (JP) | 2015-04-08 | — | — | EP | disclosed |
| CN-104379576-A | Substituted pyrrolidines as factor XIA inhibitors for the treatment of thromboembolic disorders | ONO PHARMACEUTICAL CO | 2015-02-25 | — | — | CN | disclosed |
| WO-2013174937-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | ONO PHARMACEUTICAL CO., LTD (JP) | 2013-11-28 | — | — | WO | disclosed |
| EP-0842924-B1 | Pyridine intermediates, useful in the synthesis of beta-adrenergic receptor agonists | PFIZER (US) | 2003-08-20 | — | — | EP | disclosed |
| US-6031105-A | Substituted pyridines | PFIZER INC (US) | 2000-02-29 | — | — | US | disclosed |
| US-6008361-A | Substituted pyridines | PFIZER INC. (US) | 1999-12-28 | — | — | US | disclosed |
| EP-0842924-A1 | Pyridine intermediates, useful in the synthesis of beta-adrenergic receptor agonists | PFIZER INC. (US) | 1998-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263795-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | F11, F9, F10 | GCK 3349/4885NPC1 2246/4885RAB9A 1595/4885 |
| US-10882855-B2 | Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases | F11, F9, F10 | GCK 3349/4885NPC1 2246/4885RAB9A 1595/4885 |
| US-20160287582-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | F11, F9, F10 | GCK 3349/4885NPC1 2246/4885RAB9A 1595/4885 |
| US-20170137412-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | F11, F9, F10 | GCK 3349/4885NPC1 2246/4885RAB9A 1595/4885 |
| US-20150152048-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | F11, F9, F10 | GCK 3349/4885NPC1 2246/4885RAB9A 1595/4885 |
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | DGKG, DGKA, DGKK | GCK 175/4885NPC1 1908/4885RAB9A 1548/4885 |
| US-10336741-B2 | Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases | F11, F9, F10 | GCK 3349/4885NPC1 2246/4885RAB9A 1595/4885 |
| US-20210147403-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | F11, F10, F9 | GCK 3279/4885NPC1 2339/4885RAB9A 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.